Arif Akyıldız

Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer

Taha Koray Şahin, Cemal Orhan, İbrahim Hanifi Özercan, Harun Muglu et autres

Trastuzumab deruxtecan (T-DXd) has demonstrated significant efficacy in metastatic breast cancer (mBC) with varying HER2 expression. Statins have been shown to increase HER2 membrane localization and stability, potentially enhancing responses to HER2-targeted therapies. We investigated whether statins enhance T-DXd activity through a …

tr, hu (code pays fourni par la source)

Prognostic Value of Baseline Sarcopenia and Adipose Tissue Indices in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors: A Retrospective Cohort Study

Latif Karahan, Arif Akyıldız, Taha Koray Sahin, Mustafa Arda Batu et autres

Background/Objectives: Sarcopenia, defined by reduced skeletal muscle mass, may have prognostic relevance in metastatic breast cancer. Muscle quality, reflected by adipose tissue indices, could also influence outcomes, but evidence in CDK4/6 (cyclin-dependent kinase)-inhibitor-treated patients is limited. We therefore evaluated the prognostic impact …

tr (code pays fourni par la source)

Abstract PS4-04-11: Statins enhance trastuzumab deruxtecan efficacy: Preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer

T. Sahin, Cemal Orhan, İ. Özercan, Harun Muglu et autres

Abstract Background: Trastuzumab deruxtecan (T-DXd) has demonstrated significant clinical efficacy in metastatic breast cancer (mBC) with varying HER2 expression, including HER2-low and HER2-ultralow. Statins have been shown to increase HER2 membrane localization and stability, potentially enhancing responsiveness to HER2-targeted therapies. Given this …

tr (code pays fourni par la source)

Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter Study

Mehmet Cihan İcli̇, D Karadeniz Güven, Arif Akyıldız, Ali Fuat Gürbüz et autres

Background: Microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (CRC) accounts for approximately 5% of metastatic CRC cases. Immune checkpoint inhibitors (ICIs) are the standard of care based on pivotal clinical trials; however, real-world data, particularly from low-resource countries, remain scarce, …

tr (code pays fourni par la source)

Real-World Outcomes of Neoadjuvant Pembrolizumab plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Multicenter Study from Türkiye

Rashad Ismayilov, Arzu Oğuz, Arif Akyıldız, Engin Hendem et autres

Comprehensive Review of Transarterial Chemoembolization Plus Systemic Therapy in Advanced Hepatocellular Carcinoma

Arif Akyıldız, Betül Gök Yavuz, Rashad İsmayılov, Müge Büyükaksoy et autres

tr, us (code pays fourni par la source)

Adjuvant Gemcitabine-cisplatin Combination for Biliary Tract Cancer: A Real Life Experience

Fatih Kuş, Hasan Çağrı Yıldırım, Arif Akyıldız, Ömer Denizhan Tatar et autres

Aim: Biliary tract cancers (BTCs), including gallbladder and cholangiocarcinomas, are aggressive malignancies with poor long-term survival despite surgical resection.The efficacy of adjuvant therapy in BTCs remains controversial, particularly in the absence of consistent phase 3 data supporting its survival benefit.Methods: We conducted …

“Pre-Treatment“ and “Post-Treatment” Systemic Inflammatory Markers: Is There Any Prognostic Role for Metastatic Cervical Cancer on Bevacizumab Containing Treatment?

Serkan Yaşar, Ahmet Kadıoğlu, Arif Akyıldız, Nadiye Sever et autres

Background and Objectives: Despite developments in cervical cancer (CC) treatment, an advanced stage is a poor prognostic factor. Cervical cancer is an immunogenic tumor in which viruses, like HPV, play a role in carcinogenesis. Therefore, systemic inflammatory markers (SIMs) may have prognostic …

kh, tr, in, ag (code pays fourni par la source)

Prognostic and predictive significance of the pan-immune-inflammation value in endometrial cancer patients undergoing adjuvant therapy

Elvin Chalabıyev, Rashad İsmayılov, Fatih Kuş, Arif Akyıldız et autres

Background: The pan-immune-inflammation value (PIV) has been associated with survival outcomes across various cancer types. This study investigates the association between PIV and overall and progression-free survival in endometrial cancer patients receiving adjuvant chemotherapy. Materials and methods: A retrospective analysis was conducted …

in, tr (code pays fourni par la source)

Does high PD-L1 expression reduce the risk of relapse after definitive surgery in patients with oral cavity cancer?

Parvin Babayev, Rashad İsmayılov, Oğuz Kuşçu, Arif Akyıldız et autres

Background Uncovering the molecular mechanisms of cancer pathogenesis is crucial for improving survival outcomes.Aims This study investigates the impact of programmed death ligand 1 (PD-L1) expression on the risk of progression in patients with oral squamous cell carcinoma (OSCC).Materials and methods The …

tr, in (code pays fourni par la source)

Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)

Nargız Majidova, Şendağ Yaslıkaya, Maral Martin Mıldanoğlu, Alper Coşkun et autres

Background/Aims: The treatment of hepatocellular carcinoma (HCC), which accounts for 90% of all liver cancers, is highly varied. The use of second-line treatments following progression on first-line atezolizumab and bevacizumab (Atez/Bev) for advanced HCC remains controversial. The aim of this study was …

tr, us (code pays fourni par la source)

Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey

Nargız Majidova, Shahla Aghamaliyeva, Murat Guliyev, Gülhan Dinç et autres

Managing locally advanced, or metastatic radioactive iodine-refractory differentiated thyroid cancers (RAIR-DTC) poses substantial challenges, with few available treatment options. The aim of this study was to evaluate clinical outcomes of patients receiving sorafenib as first line treatment. In addition, prognostic markers affecting …

tr, us (code pays fourni par la source)